Pharmacological aspects of the enzastaurin-pemetrexed combination in Non-Small Cell Lung Cancer (NSCLC)

Current Drug Targets

Volumn 11, Issue 1, 2010, Pages 12-28

  Giovannetti, Elisa ^a   Honeywell, Richard ^a   Hanauske, Axel R ^b   Tekle, Christina ^a,c   Kuenen, Bart ^a,e   Sigmond, Jennifer ^a   Giaccone, Giuseppe ^d   Peters, Godefridus J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY OF OSLO   (Norway)

^d NATIONAL CANCER INSTITUTE   (United States)

^e MARTINI HOSPITAL   (Netherlands)

Author keywords

Angiogenesis; Apoptosis; Drug combination; New anticancer targeted agents; Protein kinase C; Thymidylate synthase

Indexed keywords

CARBOPLATIN; CISPLATIN; CYANOCOBALAMIN; DEOXYURIDINE; DIHYDROFOLATE REDUCTASE; DOCETAXEL; ENZASTAURIN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; GLYCOGEN SYNTHASE KINASE 3BETA; METHOTREXATE; PEMETREXED; PHOSPHOLIPASE C GAMMA; PHOSPHORIBOSYLGLYCINAMIDE FORMYLTRANSFERASE; PROTEIN KINASE B; PROTEIN KINASE C ALPHA; PROTEIN KINASE C BETA; PROTEIN KINASE C DELTA; PROTEIN KINASE C EPSILON; PROTEIN KINASE C ETA; PROTEIN KINASE C GAMMA; PROTEIN KINASE C THETA; RALTITREXED; REDUCED FOLATE CARRIER; THYMIDYLATE SYNTHASE; TRANSCRIPTION FACTOR E2F1; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; GLUTAMIC ACID DERIVATIVE; GUANINE; INDOLE DERIVATIVE;

ALOPECIA; ANEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; DRUG POTENTIATION; FEBRILE NEUTROPENIA; HUMAN; INFECTION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; NEUTROPENIA; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; REVIEW; THROMBOCYTOPENIA; TUMOR VASCULARIZATION; LUNG TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; GLUTAMATES; GUANINE; HUMANS; INDOLES; LUNG NEOPLASMS;

EID: 77949429934     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945010790031009     Document Type: Review

References (177)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin 2009; 59: 225-49.
2. Buter J, Giaccone G. Medical treatment of non-small-cell lung cancer. Ann Oncol 2005; 16 (Suppl 2): ii229-32.
3. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individuals patients from 52 randomized clinical trials. Br Med J 1995; 311: 899-909.
4. Bunn PA Jr, Kelly K. New chemotherapeutic agents prolong survival and improve quality of life in non-small cell lung cancer: a review of the literature and future directions. Clin Cancer Res 1998; 4: 1087-100.
5. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002; 346: 92-8.
6. Hoang T, Schiller JH. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy. Expert Rev Anticancer Ther 2002; 2: 393-401.
7. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-44.
8. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
9. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26: 3543-51.
10. Faul MM, Gillig JR, Jirousek MR, Ballas LM, Schotten T, Kahl A, et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. Bioorg Med Chem Lett 2003; 13: 1857-9.
11. Gronberg BH, Bremnes R, Flotten O, Amundsen T, Brunsvig P, Hjelde HH, et al. Phase III study by the Norwegian Lung Cancer Study Group: pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2009; May 11 [Epub ahead of print].
12. Scagliotti G, Hanna N, Fossella F, Sugarman K, Blatter J, Peterson P, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist 2009; 14: 253-63.
13. Ciuleanu TE, Brodowicz T, Belani CP, Kim J, Krzakowski M, Laack E, et al. Maintenance pemetrexed plus bestsupportive care (BSC) versus placebo plus BSC: a phase III study. J Clin Oncol 2008; 26(15 suppl): 426s (Abstract 8011).
14. Ceppi P, Volante M, Saviozzi S, Rapa I, Novello S, Cambieri A, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 2006; 107: 1589-96.
15. Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, et al. LY231514, a pyrrolo [2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57: 1116-23.
16. Chattopadhyay S, Moran RG, Goldman ID. Pemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applications. Mol Cancer Ther 2007; 6: 404-17.
17. Takimoto CH. New antifolates: pharmacology and clinical applications. Oncologist 1996; 1: 68-81.
18. Chen VJ, Bewley JR, Andis SL, Schultz RM, Iversen PW, Shih C, et al. Preclinical cellular pharmacology of LY231514 (MTA): a comparison with methotrexate, LY309887 and raltitrexed for their effects on intracellular folate and nucleoside triphosphate pools in CCRFCEM cells. Br J Cancer 1998; 78(suppl 3): 27-34.
19. Giovannetti E, Mey V, Nannizzi S, Pasqualetti G, Marini L, Del Tacca M, et al. Cellular and pharmacogenetics foundation of synergistic interaction of pemetrexed and gemcitabine in human non small-cell lung cancer cells. Mol Pharmacol 2005; 68: 110-8.
20. Giovannetti E, Lemos C, Tekle C, Smid K, Nannizzi S, Rodriguez JA, et al. Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol 2008; 73: 1290-300.
21. Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ. Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol. 2003; 66: 431-8.
22. Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, et al. In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression. Invest New Drugs 2007; 25: 417-23.
23. Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, et al. A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression. Clin Cancer Res 2006; 12: 832-8.
24. Selvaggi G, Righi L, Ceppi P, Bacillo E, Billè A, Pandiscia S, et al. Relationship of thymidylate synthase levels to outcome of malignant pleural mesothelioma patients treated with pemetrexed-based chemotherapy. J Clin Oncol 2009; 27: 15s (Abstract 7508).
25. Zucali P, Destro A, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, et al. The role of thymidylate synthase (TS) and Excision Repair Cross-Complementing Group-1 (ERCC1) immunoistochemical expression in malignant pleural mesothelioma patients treated with pemetrexed and carboplatin. Eur J Cancer 2009, 7:2s (abstract 9127).
26. Underhill C, Goldstein D, Gorbounova VA, Biakhov MY, Bazin IS, Granov DA, et al. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer. Oncology 2007; 73: 9-20.
27. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA levels in tumor tissues and the efficacy of 5-fluorouracil in patients with non-small-cell lung cancer. Lung Cancer 2004; 45: 189-96.
28. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 529-36.
29. Peters GJ, Van der Wilt CL, Van Groeningen CJ, Smid K, Meijer S, Pinedo HM. Thymidylate synthase inhibition after administration of fluorouracil with or without leucovorin in colon cancer patients: implications for treatment with fluorouracil. J Clin Oncol 1994; 12: 2035-42.
30. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000; 6: 1322-7.
31. Smorenburg CH, Peters GJ, van Groeningen CJ, Noordhuis P, Smid K, van Riel AM, et al. Phase II study of tailored chemotherapy for advanced colorectal cancer with either 5-fluouracil and leucovorin or oxaliplatin and irinotecan based on the expression of thymidylate synthase and dihydropyrimidine dehydrogenase. Ann Oncol 2006; 17: 35-42.
32. Higashiyama M, Kodama K, Yokouchi H, Takami K, Fukushima M, Minamigawa K, et al. Thymidylate synthase and dihydropyrimidine dehydrogenase activities in non-small cell lung cancer tissues: relationship with in vitro sensitivity to 5-fluorouracil. Lung Cancer 2001; 34: 407-16.
33. Nakagawa T, Tanaka F, Otake Y, Yanagihara K, Miyahara R, Matsuoka K, et al. Prognostic value of thymidylate synthase expression in patients with p-stage I adenocarcinoma of the lung. Lung Cancer 2002; 35: 165-70.
34. Shintani Y, Ohta M, Hirabayashi H, Tanaka H, Iuchi K, Nakagawa K, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003; 104: 790-5.
35. Hashimoto H, Ozeki Y, Sato M, Obara K, Matsutani N, Nakagishi Y, et al. Significance of thymidylate synthase gene expression level in patients with adenocarcinoma of the lung. Cancer 2006; 106: 1595-601.
36. Zheng Z, Li X, Schell MJ, Boulware D, Robinson L, Sommers E, et al. Thymidylate synthase in situ protein expression and survival in stage I non-small-cell lung cancer. Cancer 2008; 112: 2765-73.
37. Edler D, Kressner U, Ragnhammar P, Johnston PG, Magnusson I, Glimelius B, et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res. 2000; 6: 488-92.
38. Rimm DL. What brown cannot do for you. Nat Biotechnol 2006; 24: 914-6.
39. Scagliotti GV, Ceppi P, Capelletto E, Novello S. Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer 2009; 10(Suppl 1): S35-40.
40. Assaraf YG. Molecular basis of antifolate resistance. Cancer Metastasis Rev 2007; 26: 153-81.
41. Assaraf YG. The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. Drug Resist Updat 2006; 9: 227-46.
42. Liani L, Rothem L, Bunni MA, Smith CA, Jansen G, Assaraf YG. Loss of folylpoly-γ-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer 2003; 103: 587-99.
43. Zhao R, Titus S, Gao F, Moran RG, Goldman ID. Molecular analysis of murine cell lines resistant to 5,10-dideazatetrahydro-folate identifies several amino acids critical to the function of folylpolyglutamate synthetase. J Biol Chem 2000; 275: 26599-606.
44. Pizzorno G, Moroson BA, Cashmore AR, Russello O, Mayer JR, Galivan J, et al. Multifactorial resistance to 5,10-dideazatetrahydrofolic acid in cell lines derived from human lymphoblastic leukemia CCRF-CEM. Cancer Res 1995; 55: 566-73.
45. Stark M, Wichman C, Avivi I, Assaraf YG. Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia. Blood 2009; 113; 4362-9.
46. Zhao R, Gao F, Goldman ID. Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem Pharmacol 2001; 61: 857-65.
47. Zhao R, Zhang S, Hanscom M, Chattopadhyay S, Goldman ID. Loss of reduced folate carrier function and folate depletion result in enhanced pemetrexed inhibition of purine synthesis. Clin Cancer Res 2005; 11: 1294-301.
48. Chattopadhyay S, Zhao R, Krupenko SA, Krupenko N, Goldman ID. The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol Cancer Ther 2006; 5: 438-49.
49. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003; 66: 403-56.
50. Gorlick R, Goker E, Trippett T, Steinherz P, Elisseyeff Y, Mazumdar M, et al. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphocytic leukemia and is associated with decreased reduced folate carrier expression. Blood 1997; 89: 1013-8.
51. Guo W, Healey JH, Meyers PA, Ladanyi M, Huvos AG, Bertino JR, et al. Mechanisms of methotrexate resistance in osteosarcoma. Clin Cancer Res 1999; 5: 621-7.
52. Zhao R, Gao F, Hanscom M, Goldman ID. A prominent low-ph methotrexate transport activity in human solid tumor cells: contribution to the preservation of methotrexate pharmacological activity in hela cells lacking the reduced folate carrier. Clin Cancer Res 2004; 10: 718-27.
53. Zhao R, Qiu A, Tsai E, Jansen M, Akabas MH, Goldman ID. The proton-coupled folate transporter: impact on pemetrexed transport and on antifolates activities compared with the reduced folate carrier. Mol Pharmacol 2008; 74: 854-62.
54. Nishizuka, Y. Intracellular signalling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258: 607-14.
55. Newton, A. C. Protein kinase C; structure, function, and regulation. J Biol Chem1995; 270: 28495-8.
56. Castagna M, Takai Y, Kaibuchi K, Sano K, Kikkawa U, Nishizuka Y. Direct activation of calciumactivated, phopholipid-dependent protein kinase by tumour-promoting phorbol esters. J Biol Chem 1982; 257: 7847-51.
57. Goekjian PG, Jirousek MR. Protein kinase C inhibitors as novel anticancer drugs. Expert Opin Investig Drugs 2001; 10: 2117-40.
58. Mackay H, Twelves CJ. Protein kinase C: a target for anticancer drugs? Endocrine Relat Cancer 2003; 10: 386-96.
59. Mackay HK, Twelves CJ. Targeting the protein kinase C family: are we there yet? Nat Rev Cancer 2007; 7: 554-62.
60. Liu Y, Su W, Thompson EA, Leitges M, Murray NR, Fields AP. Protein kinase CbetaII regulates its own expression in rat intestinal epithelial cells and the colonic epithelium in vivo. J Biol Chem 2004; 279: 45556-63.
61. Takenaga K, Takahashi K. Effects of 12-Otetradecanoylphorbol-13-acetate on adhesiveness and lung-colonising ability of Lewis lung carcinoma cells. Cancer Res 1996; 46: 375-80.
62. Clark AS, West KA, Blumberg PM, Dennis PA. Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. Cancer Res 2003; 63: 780-6.
63. Lahn M, Su C, Li S, Chedid M, Hanna KR, Graff JR, et al. Expression level of protein kinase Cα in non small cell lung cancer. Clin Lung Cancer 2004; 6: 184-9.
64. Lahn M, McClelland P, Ballard D, Mintze K, Thornton D, Sandusky G. Immunohistochemical detection of protein kinase C-beta (PKC-beta) in tumour specimens of patients with non-small cell lung cancer. Histopathology 2006; 49: 429-31.
65. Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak G, et al. Protein kinase Cα . activates RAF1 by direct phosphorylation. Nature 1993; 364: 249-52.
66. Ueda Y, Hirai S, Osada S, Suzuki A, Mizuno K, Ohno S. Protein kinase C δ . activates the MERK-ERK pathway in a manner independent of Ras and dependent on Raf. J Biol Chem 1996; 271: 23512-9.
67. Cai H, Smola U, Wixler V, Eisenmann-Tappe I, Diaz-Meco MT, Moscat J. Role of diacylglycerol-regulated protein kinase C isotypes in growth factor activation of the Raf-1 protein kinase. Mol Cell Biol 1997; 17: 732-41.
68. Marshall CJ. Cell signalling; Raf gets it together. Nature 1996; 383: 127-8.
69. Goode N, Hughes K, Woodgett JR, Parker PJ. Differential regulation of glycogen synthase kinase-3β by protein kinase C isotypes. J Biol Chem 1992; 267: 16878-82.
70. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, Bailey SN, et al. The protein kinase Cbeta-selective inhibitor, enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 2005; 65: 7462-9.
71. Teicher BA, Alvarez E, Menon K, Esterman MA, Considine E, Shih C, et al. Antiangiogenic effects of a protein kinase C β-selective small molecule. Cancer Chemother Pharmacol 2002; 49: 69-77.
72. Herbert JM. Protein kinase C: a key factor in the regulation of tumor cell adhesion to the endothelium. Biochem Pharmacol 1993; 45: 527-37.
73. Morse-Gaudio M, Connolly JM, Rose DP. Protein kinase C and its isoforms in human breast cancer cells: relationship to the invasive phenotype. Int J Oncol 1998; 12: 1349-54.
74. Keyes KA, Mann L, Sherman M, Galbreath E, Schirtzinger L, Ballard D, et al. LY317615 decreases plasma VEGF levels in human tumor xenograft-bearing mice. Cancer Chemother Pharmacol 2004; 53: 133-40.
75. Oberschmidt O, Eismann U, Schulz L, Struck S, Blatter J, Lahn MM, et al. Enzastaurin and pemetrexed exert synergistic antitumor activity in thyroid cancer cell lines in vitro . Int J Clin Pharmacol Ther 2005; 43: 603-4.
76. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS, et al. The selective protein kinase C beta inhibitor enzastaurin induces apoptosis in cutaneous T-cell lymphoma cell lines through the AKT pathway. J Invest Dermatol 2006; 126: 1641-7.
77. Spalding AC, Watson R, Davis ME, Kim AC, Lawrence TS, Ben-Josef E. Inhibition of protein kinase Cbeta by enzastaurin enhances radiation cytotoxicity in pancreatic cancer. Clin Cancer Res 2007; 13: 6827-33.
78. Podar K, Raab MS, Zhang J, McMillin D, Breitkreutz I, Tai YT, et al. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood 2007; 109: 1669-77.
79. Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008; 68: 1916-26.
80. Rizvi MA, Ghias K, Davies KM, Ma C, Weinberg F, Munshi HG, et al. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines. Mol Cancer Ther 2006; 5: 1783-89.
81. Gelardi T, Caputo R, Damiano V, Daniele G, Pepe S, Ciardiello F, et al. Enzastaurin inhibits tumours sensitive and resistant to anti-EGFR drugs. Br J Cancer 2008; 99: 473-80.
82. Jian W, Yamashita H, Levitt JM, Lerner SP, Sonpavde G. Enzastaurin shows preclinical antitumor activity against human transitional cell carcinoma and enhances the activity of gemcitabine. Mol Cancer Ther 2009; 8: 1772-8.
83. Nakajima E, Helfrich B, Chan D, Zhang Z, Hirsch FR, Chen C, et al. Enzastaurin a protein kinase Cß-selective inhibitor, inhibits the growth of SCLC and NSCLC cell lines. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24, 18S (Abstract 13138).
84. Tekle C, Giovannetti E, Sigmond J, Graff JR, Smid K, Peters GJ. Molecular pathways involved in the synergistic interaction of the PKC beta inhibitor enzastaurin with the antifolate pemetrexed in non-small cell lung cancer cells. Br J Cancer 2008; 99: 750-9.
85. Morgillo F, Martinelli E, Troiani T, Laus G, Pepe S, Gridelli C, et al. Sequence-dependent, synergistic antiproliferative and proapoptotic effects of the combination of cytotoxic drugs and enzastaurin, a protein kinase Cbeta inhibitor, in non-small cell lung cancer cells. Mol Cancer Ther 2008; 7: 1698-707.
86. Keyes K, Cox K, Treadway P,Mann L, Shih C, Faul MM, et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002; 62: 5597-602.
87. McNulty AM, Konicek BW, Lynch RL, Thornton D, Douglass L, Colligan B, et al. Enzastaurin (LY317615) suppresses signaling through the PKC and AKT pathways, inducing apoptosis, suppressing tumor-induced angiogenesis and reducing growth of human cancer xenografts. Proc AACR 2006; 47 (Abstract 1332).
88. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 2009; 9: 550-62.
89. Tang JM, He QY, Guo RX, Chang XJ. Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 2006; 51: 181-91.
90. Forde JE, Dale TC. Glycogen synthase kinase 3: a key regulator of cellular fate. Cell Mol Life Sci 2007; 64: 1930-44.
91. Green LJ, Marder P, Ray C, Cook CA, Jaken S, Musib LC, et al. Development and validation of a drug activity biomarker that shows target inhibition in cancer patients receiving enzastaurin, a novel protein kinase C-beta inhibitor. Clin Cancer Res 2006; 12: 3408-15.
92. Oh Y, Herbst RS, Burris H, Cleverly A, Musib L, Lahn M, et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. J Clin Oncol 2008; 26: 1135-41.
93. Carducci MA, Musib L, Kies MS, Pili R, Truong M, Brahmer JR, et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006; 24:4092-9.
94. Adjei A. What is the right dose? The elusive optimal biologic dose in phase I clinical trials. J Clin Oncol 2006; 24: 4054-5.
95. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123-32.
96. Gutierrez ME, Kummar S, Giaccone G. Next generation oncology drug development: opportunities and challenges. Nat Rev Clin Oncol 2009; 6: 259-65.
97. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughin M, Flynn PY, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007; 25: 1741-6.
98. Victorson D, Beaumont JL, Liepa AM. Health-related quality of life (HRQL) in patients with recurrent high-grade gliomas treated with enzastaurin. Neurol Oncol 2006; 8: 391-500.
99. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, et al: Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: Results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol 2003; 21: 1536-43.
100. Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van MR, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007; 13: 4474-81.
101. Camidge DR, Gail Eckhardt S, Gore L, O'Bryant CL, Leong S, Basche M, et al. A phase I safety, tolerability, and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced solid tumors. Anticancer Drugs 2008; 19: 77-84.
102. Butowski NA, Lamborn K, Chang S, Thornton D, DeBoer R, Page M, et al. Phase I/II study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme (GBM) or gliosarcoma [abstract]. J Clin Oncol 2007; 25(suppl): 12511
103. Hanauske AR, Lahn M, Musib LC, Weigang-Köhler K, Yilmaz E, Graefe T, et al. Phase Ib safety and pharmacokinetic evaluation of daily and twice daily oral enzastaurin in combination with pemetrexed in advanced/metastatic cancer. Ann Oncol 2009 Jun 1 [Epub ahead of print]
104. Czock D, Keller F, Rasche FM, Haussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005; 44: 61-98.
105. Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation 2002; 74: 1419-24.
106. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008; 26: 4708-13.
107. Hanauske AR, Dumez H, Piccart M, Yilmaz E, Graefe T, Gil T, et al. Pemetrexed combined with paclitaxel: a dose-finding study evaluating three schedules in solid tumors. Invest New Drugs 2009; 27: 356-65.
108. Fine HA, Kim L, Royce C, Draper D, Haggarty I, Ellinzano H, et al. Results from phase II trial of Enzastaurin (LY317615) in patients with recurrent high grade gliomas. J Clin Oncol 2005; 23: ASCO Annual Meeting Proceedings (Abstract 1504).
109. Pierchala BA, Ahrens RC, Paden AJ, Johnson EM, Jr. Nerve growth factor promotes the survival of sympathetic neurons through the cooperative function of the protein kinase C and phosphatidylinositol 3-kinasepathways. J Biol Chem 2004; 279: 27986-93.
110. Iwabu A, Smith K, Allen FD, Lauffenburger DA, Wells A. Epidermal growth factor induces fibroblast contractility and motility via a protein kinase C y-dependent pathway. J Biol Chem 2004; 279: 14551-60.
111. Cristofanilli M, Charnsangavej C, Hortobagyi GN. Angiogenesis modulation in cancer research: Novel clinical approaches. Nat Rev Drug Discov 2002; 1: 415-26.
112. Gordon MS, Margolin K, Talpaz M, Sledge GW Jr, Holmgren E, Benjamin R, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001; 19: 843-50.
113. Willett CG, Boucher Y, Duda DG, di Tomaso E, Munn LL, Tong RT, et al. Surrogate markers for antiangiogenic therapy and doselimiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005; 23: 8136-39.
114. Longo R, Gasparini G. Challenges for patient selection with VEGF inhibitors. Cancer Chemother Pharmacol 2007; 60: 151-70.
115. Ebos JM, Lee CR, Christensen JG, Mutsaers AJ, Kerbel RS. Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy. Proc Natl Acad Sci USA 2007; 104: 17069-74.
116. Hanrahan EO, Ryan AJ, Mann H, Kennedy SJ, Langmuir P, Natale RB, et al. Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer. Clin Cancer Res 2009; 15: 3600-9.
117. Kreisl TN, Kim L, Moore K, Duic P, Kotliarova S, Walling J, et al. A phase I trial of enzastaurin in patients with recurrent gliomas. Clin Cancer Res 2009; 15: 3617-23.
118. DeVita VT Jr, Chu E. A history of cancer chemotherapy. Cancer Res 2008; 68: 8643-53.
119. Stommel JM, Kimmelman AC, Ying H, Nabioullin R, Ponugoti AH, Wiedemeyer R, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 2007; 318: 287-90.
120. Sawyers CL. Mixing cocktails. Nature 2007; 449: 993-6.
121. Herbst RS, Giaccone G, Schiller JH, Natale RB, Miller V, Manegold C, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 2004; 22: 785-94.
122. Giaccone G, Herbst RS, Manegold C, Scagliotti G, Rosell R, Miller V, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 2004; 22: 777-84.
123. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small cell lung cancer. J Clin Oncol 2005; 23: 5892-99.
124. Gatzemeier U, Pluzanska A, Szczesna A, Kaukel E, Roubec J, De Rosa F, et al. Phase III study of erlotinib in combinetion with cisplatin and gemcitabine in advanced non-small cell lung cancer: The Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007; 25: 1545-52.
125. Herbst RS, Johnson DH, Mininberg E, Carbone DP, Henderson T, Kim ES, et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005; 23: 2544-55.
126. Herbst RS, O'Neill VJ, Fehrenbacher L, Belani CP, Bonomi PD, Hart L, Melnyk O, Ramies D, Lin M, Sandler A. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer. J Clin Oncol 2007; 25: 4743-50.
127. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
128. Horn L, Sandler AB. Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer. Clin Lung Cancer 2009; 10(Suppl 1): S7-16.
129. Blumenschein GR Jr, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, et al. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol 2009 Aug 3 [Epub ahead of print].
130. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul M. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. Clin Cancer Res 2001; 7: 634-40.
131. Teicher BA, Menon K, Alvarez E, Galbreath E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human HT-29 colon carcinoma and human CaKi1 renal cell carcinoma xenografts. Anticancer Res 2001; 21: 3175-84.
132. Teicher BA, Menon K, Alvarez E, Shih C, Faul MM. Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human breast cancer and ovarian cancer xenografts. Invest New Drugs 2002; 20: 241-51.
133. Meinhold-Heerlein I, Bauerschlag DO, Brautigam K, Maass N, Mundhenke C, von Kaisenberg C, et al. Effects of PKCh inhibitor enzastaurin on parental and chemoresistant ovarian cancer cell lines. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24 [Abstract 20037].
134. Fine RL, Patel J, Chabner B. A. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc Natl Acad Sci USA 1988; 85: 582-6.
135. O'Brian CA, Ward NE, Stewart JR, Chu F. Prospects for targeting protein kinase C isozymes in the therapy of drug-resistant cancer - an evolving story. Cancer Met Rev 2001; 20: 95-100.
136. Germann UA, Chambers TC, Ambudkar SV, Licht T, Cardarelli CO, Pastan I, et al. Characterisation of phosphorylation-defective mutants of human P-glycoprotein expressed in mammalian cells. J Biol Chem 1996; 271:1708-16.
137. Goodfellow HR, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton PA, et al. Protein kinase C mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 1996; 271: 13668-74.
138. Beck JF, Brugger D, Brischwein K. Anticancer drug-mediated induction of multidrug resistanceassociated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias. Jpn J Cancer Res 2001; 92: 896-903.
139. Tonkinson JL, Marder P, Andis SL, Schultz RM, Gossett LS, Shih C, et al. Cell cycle effects of antifolate antimetabolites implications for cytotoxicity and cytostasis. Cancer Chemother Pharmacol 1997; 39: 521-31.
140. Tonkinson JL, Worzalla JF, Teng CH, Mendelsohn LG. Cell cycle modulation by a multitargeted antifolate, LY231514, increases the cytotoxicity and antitumor activity of gemcitabine in HT29 colon carcinoma. Cancer Res 1999; 59: 3671-6.
141. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin Cancer Res 2007; 13: 3413-22.
142. Schwartz GK, Shah MA. Targeting the cell cycle: a new approach to cancer therapy. J Clin Oncol 2005; 23: 9408-21.
143. Giovannetti E, Mey V, Danesi R, Mosca I, Del Tacca M. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines. Clin Cancer Res 2004; 10: 2936-43.
144. Black JD. Protein kinase C-mediated regulation of the cell cycle. Front Biosci 2000; 5: D406-D23.
145. Fishman DD, Segal S, Livneh E. The role of protein kinase C in G1 and G2/M phases of the cell cycle (review). Int J Oncol 1998; 12: 181-86.
146. Yu BZ, Zheng J, Yu AM, Shi XY, Liu Y, Wu DD, et al. Effects of protein kinase C on M-phase promoting factor in early development of fertilized mouse eggs. Cell Biochem Funct 2004; 22: 291-8.
147. Houtgraaf JH, Versmissen J, van der Giessen WJ. A concise review of DNA damage checkpoints and repair in mammalian cells. Cardiovasc Revasc Med 2006; 7: 165-72.
148. Backus HH, Pinedo HM, Wouters D, Kuiper CM, Jansen G, Van Groeningen CJ et al. Differences in the induction of DNA damage, cell cycle arrest, and cell death by 5-fluorouracil and antifolates. Oncol Res 2000; 12: 231-9.
149. Lee KW, Kim SG, Kim HP, Kwon E, You J, Choi HJ, et al. Enzastaurin, a protein kinase C beta inhibitor, suppresses signaling through the ribosomal S6 kinase and bad pathways and induces apoptosis in human gastric cancer cells. Cancer Res 2008; 68: 1916-26.
150. Graves PR, Yu L, Schwarz JK, Gales J, Sausville EA, O'Connor PM, et al. The Chk1 protein kinase and the Cdc25C regulatory pathways are targets of the anticancer agent UCN-01. J Biol Chem 2000; 275: 5600-5.
151. Yu L, Orlandi L, Wang P, Orr MS, Senderowicz AM, Sausville EA, et al. UCN-01 abrogates G2 arrest through a Cdc2-dependent pathway that is associated with inactivation of the Wee1Hu kinase and activation of the Cdc25C phosphatase. J Biol Chem 1998; 273: 33455-64.
152. Guo K, Liu Y, Zhou H, Dai Z, Zhang J, Sun R, et al. Involvement of protein kinase C beta-extracellular signal-regulating kinase 1/2/p38 mitogen-activated protein kinase-heat shock protein 27 activation in hepatocellular carcinoma cell motility and invasion. Cancer Sci 2008; 99: 486-96.
153. Akiyama T, Yoshida T, Tsujita T, Shimizu M, Mizukami T, Okabe M, et al. G1 phase accumulation induced by UCN-01 is associated with dephosphorylation of Rb and CDK2 proteins as well as induction of CDK inhibitor p21/Cip1/WAF1/Sdi1 in p53-mutated human epidermoid carcinoma A431 cells. Cancer Res 1997; 57: 1495-501.
154. Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res 2006; 66: 11389-98.
155. Li W, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, et al. Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 1995; 92:10436-40.
156. Huang CL, Liu D, Nakano J, Yokomise H, Ueno M, Kadota K, et al. E2F1 overexpression correlates with thymidylate synthase and survivin gene expressions and tumor proliferation in non small-cell lung cancer. Clin Cancer Res 2007; 13: 6938-46.
157. Abe S, Kubota T, Otani Y, Furukawa T, Watanabe M, Kumai K, et al. UCN-01 (7-hydroxystaurosporine) enhances 5-fluorouracil cytotoxicity through down-regulation of thymidylate synthetase messenger RNA. Jpn J Cancer Res 2000; 91: 1192-8.
158. Hsueh CT, Kelsen D, Schwartz GK. UCN-01 suppresses thymidylate synthase gene expression and enhances 5-fluorouracil-induced apoptosis in a sequence-dependent manner. Clin Cancer Res 1998; 4: 2201-6.
159. Budman DR, Soong R, Calabro A, Tai J, Diasio R. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis. Anticancer Drugs 2006; 17: 921-8.
160. Magné N, Fischel JL, Dubreuil A, Formento P, Ciccolini J, Formento JL, et al. ZD1839 (Iressa) modifies the activity of key enzymes linked to fluoropyrimidine activity: rational basis for a new combination therapy with capecitabine. Clin Cancer Res 2003; 9: 4735-42.
161. Chu E, Koeller DM, Casey JL, Drake JC, Chabner BA, Elwood PC, et al. Autoregulation of human thymidylate synthase messenger RNA translation by thymidylate synthase. Proc Natl Acad Sci USA 1991; 88: 8977-81.
162. Peters GJ, Backus HH, Freemantle S, van Triest B, Codacci-Pisanelli G, van der Wilt CL, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194-205.
163. Mauritz R, van Groeningen CJ, Smid K, Jansen G, Pinedo HM, Peters GJ. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression after administration of 5-fluorouracil to patients with colorectal cancer. Int J Cancer 2007; 120: 2609-12.
164. Peters GJ, Tekle C, Kuenen B, Honeywell R, Sigmond J, Giovannetti G, et al. A translational study on the protein kinase C-β inhibitor enzastaurin and the thymidylate synthase inhibitor pemetrexed. AACR Meeting Abstracts 2007; [Abstract 1820].
165. Honeywell R, Laan AC, van Groeningen CJ, Strocchi E, Ruiter R, Giaccone G, et al. The determination of gemcitabine and 2′-deoxycytidine in human plasma and tissue by APCI tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2007; 847: 142-52.
166. Tabatabai G, Frank B, Wick A, Lemke D, von Kürthy G, Obermuller U, et al. Synergistic antiglioma activity of radiotherapy and enzastaurin. Ann Neurol 2007; 61: 153-61.
167. Yuan A, Yu CJ, Shun CT, Luh KT, Kuo SH, Lee YC, et al. Total cyclooxygenase-2 mRNA levels correlate with vascular endothelial growth factor mRNA levels, tumor angiogenesis and prognosis in non-small cell lung cancer patients. Int J Cancer 2005; 115: 545-55.
168. Shaik MS, Chatterjee A, Jackson T, Singh M. Enhancement of antitumor activity of docetaxel by celecoxib in lung tumors. Int J Cancer 2006; 118: 396-404.
169. Dirix LY, Vermeulen PB, Hubens G, Benoy I, Martin M, De Pooter C, et al. Serum basic fibroblast growth factor and vascular endothelial growth factor and tumour growth kinetics in advanced colorectal cancer. Ann Oncol 1996; 7: 843-48.
170. Bianco C, Giovannetti E, Ciardiello F, Mey V, Nannizzi S, Tortora G, et al. Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer. Clin Cancer Res 2006; 12: 7099-107.
171. Mey V, Giovannetti E, De Braud F, Nannizzi S, Curigliano G, Verweij F, et al. In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer 2006; 95: 289-97.
172. Feng FY, Varambally S, Tomlins SA, Chun PY, Lopez CA, Li X, et al. Role of epidermal growth factor receptor degradation in gemcitabine-mediated cytotoxicity. Oncogene 2007; 26: 3431-9.
173. Chun PY, Feng FY, Scheurer AM, Davis MA, Lawrence TS, Nyati MK. Synergistic effects of gemcitabine and gefitinib in the treatment of head and neck carcinoma. Cancer Res 2006; 66: 981-8.
174. Graff J. Enzastaurin dramatically enhances the efficacy of temozolomide in glioblastoma cells and xenograft. Proceedings EORTC-PAMM Winter Meeting 2009 [Abstract 16].
175. Sakamoto KM, Frank DA. CREB in the pathophysiology of cancer: implications for targeting transcription factors for cancer therapy. Clin Cancer Res 2009; 15: 2583-7.
176. Seo HS, Liu DD, Bekele BN, Kim MK, Pisters K, Lippman SM, et al. Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer. Cancer Res 2008; 68: 6065-73.
177. Rothem L, Stark M, Assaraf YG. Impaired CREB-1 phosphorylation in antifolate-resistant cell lines with down-regulation of the reduced folate carrier gene. Mol Pharmacol 2004; 66: 1536-43.